SEATTLE, May 7, 2013 /PRNewswire/ -- Plandai
Biotechnology, Inc. (OTCQB: PLPL), a producer of highly
bioavailable plant extracts for industries including health,
wellness, nutraceutical, and pharmaceutical, today announced the
formation of Phyto Pharmacare, Inc., a Delaware corporation, which will oversee all
aspects of developing and marketing Phytofare™ extracts for
pharmaceutical and drug applications.
Plandai Chief Executive Officer Roger
Duffield commented, "As a management team, we felt it
necessary to differentiate the purely pharmaceutical operations
from our farming, production and nutraceutical business. Taking our
Phytofare™ extracts and seeking FDA clearance to market them to
treat specific diseases brings unique challenges and requires an
entirely different focus. The creation of Phyto Pharmacare, which
will operate under a license from Plandai, enables that division to
focus on specific drug targets and take our products through the
various stages of clinical trials and FDA approval."
Initially, Phyto Pharmacare will focus on using its Phytofare™
Catechin Extract as both a cure for and prevention of
malaria. Malaria is a parasite infection transmitted by
mosquitoes and primarily located in sub-Sahara Africa and southern
Asia, where it results in nearly a
million deaths annually.
Mr. Duffield explained, "Malaria is one of great plagues that
still kills way too many people, most of whom are children and the
elderly located in some of the poorest and most remote areas of the
world where access to life-saving medicine is either unaffordable
or unavailable. With drug-resistant strains of the parasite
now spreading across Asia, we
could soon be facing a pandemic. The catechins found in green
tea are well documented for their anti-malarial properties, but low
human bioavailability (absorption) has limited its effectiveness as
a drug. We believe that the high bioavailability of our
Phytofare™ extract will finally yield a suitable drug for treating
not only malaria but also other blood-borne parasitic
infections."
Phyto Pharmacare will shortly begin validating the
bioavailability of Phytofare™ Catechin Extract in human studies and
is just completing in-vitro studies of its anti-malarial properties
compared against other catechin extracts at St. George's University of London in England.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. and its subsidiaries develop highly
bioavailable, phytonutrient rich extracts which are being utilized
to deliver a new family of drugs to safely and affordably treat a
multitude of diseases and conditions. Plandai Biotechnology
controls every aspect of the process, from growing the raw
materials on its farms in South
Africa, to producing its patented Phytofare™ extracts
in-house, allowing the Company to guarantee the continuity of
supply as well as quality control throughout the entire
process. Targeted industries for the Company's products
include food and beverage, cosmeceutical, wellness, nutraceutical,
anti-aging, and pharmaceutical. For more information, please
visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements
and involve risks and uncertainties. Results, events and
performances could vary from those contemplated. These statements
involve risks and uncertainties which may cause actual results,
expressed or implied, to differ from predicted outcomes. Risks and
uncertainties include product demand, market competition, and
Plandai's ability to meet current or future plans. Investors should
study and understand all risks before making an investment
decision. Readers are recommended not to place undue reliance on
forward-looking statements or information. Plandai is not obliged
to publicly release revisions to any forward-looking statement, to
reflect events or circumstances afterward, or to disclose
unanticipated occurrences, except as required under applicable
laws.
Contact:
Andrew Beyer
Phone: 619-202-7456
Email: investor@Plandaibiotech.com
SOURCE Plandai Biotechnology, Inc.